Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13171302 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL19326428 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL13607677 | 0.89 | ALDH1A1 (0.48) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL18521255 | 0.89 | ALDH1A1 (0.48) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL12973185 | 0.89 | ALDH1A1 (0.48) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL24371811 | 0.88 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL1844446 | 0.88 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL19326334 | 0.88 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL930473 | 0.88 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL17560666 | 0.88 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | Atea Pharmaceuticals, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | Atea Pharmaceuticals, Inc. (US) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | ALDH1A1 2186/4885KMT2A 3167/4885TDP1 264/4885 |
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | PNP, SLC29A2, NT5C2 | ALDH1A1 495/4885KMT2A 4130/4885TDP1 1070/4885 |
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | PNP, SLC29A2, NT5C2 | ALDH1A1 426/4885KMT2A 4166/4885TDP1 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.